Review
Pharmacology & Pharmacy
Chuanlin Wang, Pengning Gao, Jiali Xu, Shanling Liu, Wenda Tian, Jiayu Liu, Lan Zhou
Summary: This article reviews the role of natural phytochemicals in alleviating the side effects of BRCA mutant ovarian cancer cells and PARP inhibitors, and finds that these substances have significant alleviating effects on atherosclerosis, nausea, and vomiting.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Stergios Boussios, Elie Rassy, Michele Moschetta, Aruni Ghose, Sola Adeleke, Elisabet Sanchez, Matin Sheriff, Cyrus Chargari, Nicholas Pavlidis
Summary: DNA damage is a hallmark of cancer. Epithelial ovarian cancer (EOC) and prostate cancer often have defects in DNA damage response (DDR) pathways. PARP inhibitors are a therapeutic strategy for EOC and prostate cancer, particularly in tumors with HR deficiency. Genetic testing plays an increasingly important role in the treatment of ovarian and prostate cancer patients.
Article
Oncology
Maria Ornella Nicoletto, Alessandra Baldoni, Francesco Cavallin, Andrea Grego, Cristina Falci, Margherita Nardin, Enzo Mammano, Eleonora Lai, Valter Torri
Summary: This study aimed to investigate the response of platinum-sensitive advanced ovarian cancer patients to PARP inhibitor treatment. The results showed that receiving pegylated liposomal doxorubicin-oxaliplatin treatment improved progression-free survival and overall survival in platinum-sensitive advanced ovarian cancer patients. In BRCA-mutated patients, pegylated liposomal doxorubicin-oxaliplatin treatment improved progression-free survival.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Anna P. Loboda, Leonid S. Adonin, Svetlana D. Zvereva, Dmitri Y. Guschin, Tatyana V. Korneenko, Alexandra V. Telegina, Olga K. Kondratieva, Sofia E. Frolova, Nikolay B. Pestov, Nick A. Barlev
Summary: The tumor suppressor genes BRCA1 and BRCA2 are associated with early-onset breast and ovarian cancers. This review explores the hypothesis that Alu mobile genomic elements may be involved in the extensive mutagenesis of these genes. Understanding the connection between mutations in BRCA1 and BRCA2 and genome stability and DNA repair mechanisms is crucial for therapeutic decision-making in cancer treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Panagiota Economopoulou, Ioannis Kotsantis, Aristotelis Bamias
Summary: Advanced epithelial ovarian cancer is a major cause of gynecological cancer deaths in western countries. Mutations in BRCA1 and BRCA2 genes increase the risk of multiple cancers and personalized treatment is important for patients with these mutations. Incorporating BRCA-targeted therapies has improved outcomes in advanced EOC.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
(2021)
Article
Cell Biology
Shu-Ping Wang, Shi-Qi Wu, Shi-Hui Huang, Yi-Xuan Tang, Liu-Qiong Meng, Feng Liu, Qi-Hua Zhu, Yun-Gen Xu
Summary: Repression of the oncogenic transcription factor FOXM1 using FOXM1 shRNA or FDI-6 inhibitor sensitizes BRCA-proficient TNBC to the PARP inhibitor Olaparib by regulating cell cycle and DNA damage repair pathways. Simultaneously targeting FOXM1 and PARP1/2 is an innovative therapy for more patients with TNBC.
CELL DEATH & DISEASE
(2021)
Review
Biochemistry & Molecular Biology
Sidrah Shah, Rachelle Rachmat, Synthia Enyioma, Aruni Ghose, Antonios Revythis, Stergios Boussios
Summary: Prostate cancer ranks fifth in cancer-related mortality in men worldwide, and DNA damage is implicated in its pathogenesis. Impaired DDR pathways play a role in prostate carcinogenesis, with germline or somatic mutations in DDR genes being found in primary and metastatic prostate cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Fergus Keane, Catherine A. O'Connor, Wungki Park, Thomas Seufferlein, Eileen M. O'Reilly
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related death in the US. PDAC with gBRCA1/2 mutations has a more favorable prognosis and additional treatment options compared to an unselected PDAC cohort. Efforts are being made to expand the use of PARP inhibitors to other genetic mutations associated with deficient DNA damage repair (DDR). Resistance to platinum-based chemotherapies and PARPi remains a challenge in improving long-term outcomes.
Review
Biochemistry & Molecular Biology
Mihaela Raluca Radu, Alina Pradatu, Florentina Duica, Romeo Micu, Sanda Maria Cretoiu, Nicolae Suciu, Dragos Cretoiu, Valentin Nicolae Varlas, Viorica Elena Radoi
Summary: Ovarian cancer is a common cause of death in women, with early diagnosis being crucial. Genomic instability is a hallmark of the cancer, and there is diversity within different subtypes. Early detection leads to a favorable prognosis.
Review
Oncology
Dylan P. McClurg, Gordan Urquhart, Trevor McGoldrick, Subarnarekha Chatterji, Zosia Miedzybrodzka, Valerie Speirs, Beatrix Elsberger
Summary: Male breast cancer is a rare disease with limited treatment evidence for BRCA-related cases, highlighting the need for national and global collaborative efforts. Transformative clinical advancements with PARP inhibitors in female breast cancer and prostate cancer provide valuable insights.
Article
Pathology
Annamaria Salvati, Ileana Carnevali, Elena Alexandrova, Sofia Facchi, Susanna Ronchi, Laura Libera, Nora Sahnane, Domenico Memoli, Jessica Lamberti, Sonia Amabile, Stefano Pepe, Roberta Tarallo, Fausto Sessa, Alessandro Weisz, Maria Grazia Tibiletti, Francesca Rizzo
Summary: This study evaluated the mutational profile of ovarian cancer patients in Italy using next-generation sequencing, identifying TP53 as the gene with highest mutational rate and detecting a subset of patients with pathogenic variants sensitive to PARP-inhibitor therapies. Germline analysis revealed carrier of pathogenic germline variants in actionable genes.
EXPERIMENTAL AND MOLECULAR PATHOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Ting Hong, Guang Lei, Xue Chen, He Li, Xiaoye Zhang, Nayiyuan Wu, Yu Zhao, Yilei Zhang, Jing Wang
Summary: The study reveals that ferroptosis contributes to the efficacy of PARP inhibitor olaparib by downregulating SLC7A11 expression. Interference with ferroptosis leads to resistance to olaparib, while boosting ferroptosis enhances sensitivity to PARP inhibitors in BRCA-proficient ovarian cancer cells.
Article
Oncology
Mattia Cremona, Cassandra J. Vandenberg, Angela M. Farrelly, Stephen F. Madden, Clare Morgan, Roshni Kalachand, Jessica N. McAlpine, Sinead Toomey, David G. Huntsman, Liam Grogan, Oscar Breathnach, Patrick Morris, Mark S. Carey, Clare L. Scott, Bryan T. Hennessy
Summary: The study found that XIAP protein expression is increased in BRCA1-mutated cancers, associated with optimization of PARP and NF-kB activation. BRCA1-mutated cells are more sensitive to IAP inhibitors, and treatment with IAP inhibitors can restore the efficacy of PARP inhibitors.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Cai M. Roberts, Mehida Rojas-Alexandre, Ruth E. Hanna, Z. Ping Lin, Elena S. Ratner
Summary: This study identified that TGF-β and epithelial to mesenchymal transition (EMT) sensitize ovarian cancer cells to olaparib by downregulating the genes responsible for homologous recombination (HR). Additionally, mesenchymal cells also displayed sensitivity to olaparib, cisplatin, and the DNA-PK inhibitor Nu-7441. Therefore, treating disseminated, mesenchymal tumors may expand the clinical utility of PARP inhibitors and similar agents.
Review
Chemistry, Medicinal
Mauro Francesco Pio Maiorano, Brigida Anna Maiorano, Annalucia Biancofiore, Gennaro Cormio, Evaristo Maiello
Summary: This review comprehensively summarizes the pharmacological properties of niraparib, as well as its efficacy and safety data in maintenance therapy for platinum-sensitive OC patients, and discusses the future development of this agent.
Article
Oncology
Dimitrios Nasioudis, Stefan Gysler, Nawar Latif, Lory Cory, Robert L. Giuntoli II, Sarah H. Kim, Fiona Simpkins, Lainie Martin, Emily M. Ko
Summary: The prevalence of ERBB2 gene amplification was investigated among patients with gynecologic malignancies. The study found that ERBB2 amplification is frequently encountered in uterine serous carcinoma and mucinous ovarian carcinoma, but less common in endometrioid endometrial carcinoma.
GYNECOLOGIC ONCOLOGY
(2024)